Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 13, 2026
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on May 6, 2026, under the EU Market Abuse Regulation (MAR) Safe Harbour Rules.
Key Financial Metrics and Capital Allocation
This filing focuses on capital return activities rather than operational financial performance (revenue, profit, or cash flow). Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period beginning February 4, 2026.
- Specific Programme (May 6, 2026): Up to DKK 11,200,000,010.45 for B shares between May 6, 2026, and February 1, 2027.
- Accumulated Repurchases (as of July 10, 2026): 23,984,179 B shares purchased since February 4, 2026.
- Total Value Repurchased (since Feb 4, 2026): DKK 6,534,545,458.
- Average Purchase Price (since Feb 4, 2026): DKK 272.45 per B share.
- Treasury Shares Held: 41,169,480 B shares (0.9% of total share capital).
Material Changes and Recent Transactions
The filing details specific transactions executed between July 6 and July 10, 2026, under the May 6 programme:
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| July 6, 2026 | 195,000 | 323.77 | 63,135,020 |
| July 7, 2026 | 195,000 | 327.75 | 63,910,282 |
| July 8, 2026 | 195,000 | 320.62 | 62,521,793 |
| July 9, 2026 | 195,000 | 320.72 | 62,540,384 |
| July 10, 2026 | 195,000 | 321.34 | 62,662,008 |
Accumulated under May 6 Programme: 9,225,000 shares for a total value of DKK 2,734,545,468.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period starting February 4, 2026. The company maintains its purpose to drive change in defeating serious chronic diseases, particularly diabetes.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies. It notes that transaction details are published on the company website and that the repurchases are conducted in compliance with EU regulations.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion programme (approx. DKK 8.47 billion remaining as of July 10, 2026).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 320–327.
- Review the total share capital (4,465,000,000 shares) to assess the dilution impact of the 0.9% treasury holding.
- Check the company website (novonordisk.com) for daily transaction updates as required by the Safe Harbour Rules.